Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Kidney Dis. 2011 Nov;58(5):729-36. doi: 10.1053/j.ajkd.2011.06.020. Epub 2011 Aug 26.

Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.

Collaborators (191)

Kerr P, Champion de Crespigny PJ, Langham R, Jackson B, Jerums G, d'Emden M, Packham D, Roger S, Yue D, Karrasch J, Isbel N, Thomas M, Simpson R, Cutfield R, Drury PL, Manning P, Prager R, Schernthaner G, Engelen W, Meeus G, Van Biesen W, Van Gaal L, Johansen LB, Lervang HH, Madsbad S, Mathiesen E, Perrild H, Prange A, Rossing P, Steffensen G, Thorsteinsson B, Urhammer S, Vestergaard H, Bataille P, Faller B, Godin M, Meurette A, Verier Mine O, Zaoui P, Gero L, Jermendy G, Nagy J, Somogyi A, Tamas G, Vandorfi G, Voros P, Winkler G, Adawi F, Benchetrit S, Cohen Y, Harman Boehm I, Herskovitz A, Karnieli E, Kristal B, Raz I, van Dijk D, Wainstein J, Yagil Y, Yerushalmi Y, Albertazzi A, Bigazzi R, Boero R, Bonora E, Corsi A, Dal Canton A, DeFerrari G, Del Prato S, Fioretto P, Gesualdo L, Malberti F, Pugliese G, Trevisan R, Zoccali C, Zuccala A, Brouwer CB, Elte JW, Heeg JE, Hoogenberg K, Hoogma RP, Lieverse LA, van Loon BJ, Storms FG, Valentijn RM, van der Meulen J, Verhoeven RP, Woittiez-Almelo AJ, Franek E, Gorska M, Pupek Musialik D, Wiecek A, Duarte JS, de Alvaro Moreno F, Esmatjes Mompo E, Goicoechea MA, Gorostidi Perez M, Gorriz Teruel JL, Lens Neo XM, Pascual Izuel JM, Praga Gerente M, Romero Gonzalez R, Vallés M, Ekelund M, Frid A, Lins PE, Tencer J, Bilous R, Franke B, Arbie JN, Hassanein M, Heller S, Marshall S, Mikhail A, Tindall H, Vora J, Winocour P, Bailey GR, Cattran D, Hladunewich M, Leiter LA, Ross SA, Tildesley HD, Woo V, Anderson R, Aronoff S, Barrer B, Behnke A, Bissette S, Blevins T, Blumenthal S, Buckalew VM, Burgos Calderón R, Campese V, Cherlin R, Chinn J, Dixon T, Dúrense H, Eisner G, Fadem S, Fitz-Patrick D, Galphin C, Gavin L, Goldberg R, Gollapudi GM, Goral S, Grubb S, Henry RR, Hershon K, Jonson D, Kaplan R, Katz MA, Kaye W, Klein E, Klonoff D, Kramer N, Levine B, Lohr J, Lopes Virilla MF, McGill JB, Mersey JH, Michaels R, Morin D, Myers L, Pohl MA, Pullman J, Reisin E, Rodelas R, Rosendorff C, Schulman G, Schwartz AB, Schwartz S, Shapiro J, Sharon Z, Sinsakul MV, Smith RD, Soler N, Solomon R, Sugimoto D, Turner J, Velásquez M, Weiss D, Wiegmann TB, Williams ME, Wise J, Yale S, Young B, Young D, Zeig S, Zemel L, Zieve FJ, Zigrang W, Cangiano JL.

Author information

1
Rush University Medical Center, Chicago, IL, USA. csg@rush.edu

Erratum in

  • Am J Kidney Dis. 2012 Feb;59(2):318.

Abstract

BACKGROUND:

Sulodexide, a heterogenous group of sulfated glycosaminoglycans, includes low-molecular-weight heparin (~80% ± 8%), high-molecular-weight heparin (~5% ± 3%), and dermatan (~20% ± 8%), with a mean molecular weight of ~9 kDa. The drug is absorbed orally and has no anticoagulant effect in the doses used. Small preliminary studies consistently showed sulodexide to be associated with decreased albuminuria in patients with diabetes.

STUDY DESIGN:

We conducted a multicenter placebo-controlled double-blinded study to determine the effect of sulodexide on urine albumin excretion in patients with type 2 diabetic nephropathy.

SETTING & PARTICIPANTS:

Patients with type 2 diabetes and urine albumin-creatinine ratios (ACRs) of 35-200 mg/g in men and 45-200 mg/g in women were enrolled. Serum creatinine level was <1.5 mg/dL. Blood pressure goal was 130/80 mm Hg. A maximum US Food and Drug Administration-approved dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker for a minimum of 4 months before randomization was required.

INTERVENTION:

The study drug was sulodexide, 200 mg/d.

OUTCOME & MEASUREMENTS:

The primary end point was normoalbuminuria (ACR <20 mg/g and a decrease >25%) or 50% decrease in baseline ACR.

RESULTS:

In 1,056 randomly assigned patients with a mean baseline ACR of 107.8 ± 83.7 mg/g, comparing the sulodexide versus placebo groups, the primary end point was achieved in 16.5% versus 18.4%; normoalbuminuria, in 7.9% versus 6.1%; and a 50% decrease in albuminuria, in 15.4% versus 17.6%. The relative probability of any given change in albuminuria was identical in both groups.

LIMITATIONS:

We were unable to determine whether the administered sulodexide was absorbed from the gastrointestinal tract.

CONCLUSION:

Sulodexide failed to decrease urine albumin excretion in patients with type 2 diabetic nephropathy and microalbuminuria.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00130208.

PMID:
21872376
DOI:
10.1053/j.ajkd.2011.06.020
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center